Insomnia in Medical Technology
Navigation Links
Insomnia in Medical Technology
... results for ITI-007 from a Phase II trial in insomnia characterized by difficulty in maintaining sleep, also known as sleep maintenance insomnia (SMI). These data demonstrate that ITI-007 is ...
ABOUT SLEEP MAINTENANCE DISORDERS
From insomnia to sleep apnea, sleep disorders disrupt the sleep ...
... agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled ... Circadian rhythm sleep disorders include insomnia associated with shift work (overnight, rotating ... agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomized controlled ...
... indicated for use as-needed for the treatment of insomnia when a middle of the night awakening is followed ... awakening is the most frequently reported insomnia symptom. This study estimates that 35% of ... developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed ...
... were eligible for the study if symptoms of insomnia were chronic and LPS was greater than 30 ... of tasimelteon to treat the symptoms of insomnia acutely and chronically both in a model of transient insomnia and in patients with chronic primary insomnia. ...
... 2a clinical trial of APD125 for the treatment of insomnia in an oral presentation at the SLEEP 2008 22nd ... that is being evaluated for the treatment of insomnia in patients who have difficulty maintaining sleep ... receptor. The vast majority of approved drugs for insomnia work by activating the GABA-A receptor complex in ...
... is developing Intermezzo(R) for the treatment of insomnia characterized by middle-of-the-night ... "One significant challenge in trying to help insomnia patients return to sleep after a ... awakenings are the most frequently reported insomnia symptom in the general population, with 35 ...
... time over 8 weeks in patients with co-morbid insomnia and major depressive disorder (MDD) who were ... be considered a viable treatment option for the insomnia MDD patients experience and help them get the ... in an earlier study of Ambien CR in patients with insomnia and co-morbid general anxiety disorder (GAD). It ...
... buffered sublingual formulation designed to treat insomnia in patients who awaken in the middle-of-the-night ... sleep-lab study of Intermezzo(R) involving 82 insomnia patients. As announced in June 2007, the ... awakenings are the most frequently reported insomnia symptom in the general population, with 35 ...
... Role of AMBIEN CR in Effectively Managing insomnia to Improve Quantity and Quality of ... patients taking placebo. Patients with chronic insomnia can have a higher frequency of work-related ... study included 728 patients with chronic primary insomnia (478 treated with AMBIEN CR and 250 treated with ...
... discovered by Arena that is being evaluated in insomnia patients who have difficulty maintaining sleep ... of APD125 for the treatment of insomnia patients who have difficulty maintaining sleep. ... receptor. The vast majority of approved drugs for insomnia activate the GABA-A receptor in the brain, ...
... of 451 patients age 18 or older with chronic insomnia were randomized in this clinical study. Patients ... effects, pharmacological tolerance, rebound insomnia or withdrawal symptoms. Poster 525 will be ... all other prescription medications indicated for insomnia are classified as Schedule IV controlled ...
... nausea (28% vs. 18%), dizziness (25% vs. 24%), somnolence (22% vs. 9%), insomnia (17% vs. 12%), asthenia (14% vs. 12%), and constipation (14% vs. 6%). In ... vs. 48%), dyskinesia (47% vs. 31%), extrapyramidal syndrome (28% vs. 26%), insomnia (27% vs. 22%), dizziness (26% vs. 25%), accidental injury (17% vs. 15%), ...
... and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness ... vs 17%), anorexia (23% vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain ...
... vs 17%), anorexia (23% vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain ... and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness ...
... activity in addition to its potential in treating sleep maintenance insomnia and psychosis in patients," stated Sharon Mates, Ph.D., Chairman and ... is being developed simultaneously for the treatment of sleep maintenance insomnia in the general population. Due to the unique separation of D2 and 5HT2A ...
... from 0.5 to 4.0 mg) will be compared to placebo. About Insomnia insomnia is a prevalent disorder that drives almost $5 billion in worldwide sales ... showed that 54% of the respondents experienced a minimum of one symptom of insomnia at least a few nights a week. Of those, respondents complained primarily ...
... reported central nervous system symptoms (including dizziness [28.1%], insomnia [16.3%], impaired concentration [8.3%], somnolence [7.0%], abnormal dreams ... fatigue (7%), headache (5%), rash (5%), sinusitis (4%), depression (4%), insomnia (4%), and abnormal dreams (4%). The dose of ATRIPLA is one tablet ...
... reported central nervous system symptoms (including dizziness [28.1%], insomnia [16.3%], impaired concentration [8.3%], somnolence [7.0%], abnormal dreams ... fatigue (7%), headache (5%), rash (5%), sinusitis (4%), depression (4%), insomnia (4%), and abnormal dreams (4%). The dose of ATRIPLA is one tablet ...
... in severity. The most frequently reported adverse events for VYVANSE were insomnia (8 percent), decreased appetite (6 percent), anorexia (4 percent) and ... were decreased appetite (4 percent), upper abdominal pain (4 percent), insomnia (2 percent), upper respiratory tract infection (2 percent) and vomiting (2 ...
... reported central nervous system symptoms (including dizziness [28.1%], insomnia [16.3%], impaired concentration [8.3%], somnolence [7.0%], abnormal dreams ... fatigue (7%), headache (5%), rash (5%), sinusitis (4%), depression (4%), insomnia (4%), and abnormal dreams (4%). The dose of ATRIPLA is one tablet ...
... reported central nervous system symptoms (including dizziness [28.1%], insomnia [16.3%], impaired concentration [8.3%], somnolence [7.0%], abnormal dreams ... fatigue (7%), headache (5%), rash (5%), sinusitis (4%), depression (4%), insomnia (4%), and abnormal dreams (4%). The dose of ATRIPLA is one tablet ...
... vs. 3%), headache (11.1% vs. 10%), constipation (11.1% vs. 5.6%), vomiting (11.1% vs. 5.6%), dyspepsia (11.1% vs. 3.3%), somnolence (11.1% vs. 3.3%), insomnia (10.0% vs. 3.3%) and sedation (10.0% vs. 4.4%). Lurasidone had a lower overall discontinuation rate (42.2%) compared to placebo (48.8%) with few ...
... were fatigue/asthenia (65 percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection ...
... were fatigue/asthenia (65 percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection ...
... cough (22%), arthralgia (21%), lower-limb edema (21%), malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased weight (16%), back pain (15%) and paresthesia (15%). Caution is advised when bisphosphonates are administered with ...
... injection site pain, peripheral oedema, dizziness, muscle spasms, nausea, contusion, diarrhoea, bone marrow disorder, influenza like illness, insomnia and pruritus. Reoccurrence of thrombocytopenia and bleeding after cessation of treatment and increased bone marrow reticulin have been ...
... of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections. See "Warnings ...
... (33% vs 16%), pyrexia (29% vs 19%), fatigue (29% vs 26%), lymphopenia (24% vs 17%), anorexia (23% vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% ...
... or equal to 5 percent higher patient incidence in Nplate versus placebo) were Arthralgia (26 percent, 20 percent), Dizziness (17 percent, 0 percent), insomnia (16 percent, 7 percent), Myalgia (14 percent, 2 percent), Pain in Extremity (13 percent, 5 percent) , Abdominal Pain (11 percent, 0 percent), ...
... (33% vs 16%), pyrexia (29% vs 19%), fatigue (29% vs 26%), lymphopenia (24% vs 17%), anorexia (23% vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% ...
... of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections. See "Warnings ...
... cough (22%), arthralgia (21%), lower-limb edema (21%), malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased weight (16%), back pain (15%) and paresthesia (15%). Caution is advised when bisphosphonates are administered with ...
... of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for ...
... agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled ... Circadian rhythm sleep disorders include insomnia associated with shift work (overnight, rotating ... agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomized controlled ...
... indicated for use as-needed for the treatment of insomnia when a middle of the night awakening is followed ... awakening is the most frequently reported insomnia symptom. This study estimates that 35% of ... developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed ...
... were eligible for the study if symptoms of insomnia were chronic and LPS was greater than 30 ... of tasimelteon to treat the symptoms of insomnia acutely and chronically both in a model of transient insomnia and in patients with chronic primary insomnia. ...
HealthMedia and Aetna to Study Online Insomnia and Depression Interventions
... which will provide HealthMedia's Overcoming(TM) insomnia and Overcoming(TM) Depression online ... conditions. "We recognize that depression and insomnia are both problems that are major drivers of ... hrs/week vs. 1.5 hrs/week) -- Those with severe insomnia miss work twice as often as good sleepers -- ...... 2a clinical trial of APD125 for the treatment of insomnia in an oral presentation at the SLEEP 2008 22nd ... that is being evaluated for the treatment of insomnia in patients who have difficulty maintaining sleep ... receptor. The vast majority of approved drugs for insomnia work by activating the GABA-A receptor complex in ...
... is developing Intermezzo(R) for the treatment of insomnia characterized by middle-of-the-night ... "One significant challenge in trying to help insomnia patients return to sleep after a ... awakenings are the most frequently reported insomnia symptom in the general population, with 35 ...
... time over 8 weeks in patients with co-morbid insomnia and major depressive disorder (MDD) who were ... be considered a viable treatment option for the insomnia MDD patients experience and help them get the ... in an earlier study of Ambien CR in patients with insomnia and co-morbid general anxiety disorder (GAD). It ...
... buffered sublingual formulation designed to treat insomnia in patients who awaken in the middle-of-the-night ... sleep-lab study of Intermezzo(R) involving 82 insomnia patients. As announced in June 2007, the ... awakenings are the most frequently reported insomnia symptom in the general population, with 35 ...
Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
... discovered by Arena with the potential to reduce insomnia symptoms and improve sleep maintenance ... tolerability of APD125 in patients with primary insomnia characterized by difficulty maintaining sleep. ... sleep maintenance and quality for patients with insomnia without the potential for dependence or impairing ...Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
... announced it has initiated a sleep maintenance insomnia (SMI) Phase 2 clinical study using its drug ... women, and in other disorders where insomnia is a problem, including ... Sleep Maintenance Disorders From nightmares to insomnia to sleep apnea, sleep disorders disrupt the sleep ...... Role of AMBIEN CR in Effectively Managing insomnia to Improve Quantity and Quality of ... patients taking placebo. Patients with chronic insomnia can have a higher frequency of work-related ... study included 728 patients with chronic primary insomnia (478 treated with AMBIEN CR and 250 treated with ...
... discovered by Arena that is being evaluated in insomnia patients who have difficulty maintaining sleep ... of APD125 for the treatment of insomnia patients who have difficulty maintaining sleep. ... receptor. The vast majority of approved drugs for insomnia activate the GABA-A receptor in the brain, ...
... of 451 patients age 18 or older with chronic insomnia were randomized in this clinical study. Patients ... effects, pharmacological tolerance, rebound insomnia or withdrawal symptoms. Poster 525 will be ... all other prescription medications indicated for insomnia are classified as Schedule IV controlled ...
... nausea (28% vs. 18%), dizziness (25% vs. 24%), somnolence (22% vs. 9%), insomnia (17% vs. 12%), asthenia (14% vs. 12%), and constipation (14% vs. 6%). In ... vs. 48%), dyskinesia (47% vs. 31%), extrapyramidal syndrome (28% vs. 26%), insomnia (27% vs. 22%), dizziness (26% vs. 25%), accidental injury (17% vs. 15%), ...
... and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness ... vs 17%), anorexia (23% vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain ...
... vs 17%), anorexia (23% vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain ... and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness ...
Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
... tolerated in this population of healthy volunteers. About Insomnia insomnia is a prevalent disorder that drives a multi-billion dollar market of ... showed that 54% of the respondents experienced a minimum of one symptom of insomnia at least a few nights a week. Of those, respondents complained primarily ...Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
... activity in addition to its potential in treating sleep maintenance insomnia and psychosis in patients," stated Sharon Mates, Ph.D., Chairman and ... is being developed simultaneously for the treatment of sleep maintenance insomnia in the general population. Due to the unique separation of D2 and 5HT2A ...... activity in addition to its potential in treating sleep maintenance insomnia and psychosis in patients," stated Sharon Mates, Ph.D., Chairman and ... is being developed simultaneously for the treatment of sleep maintenance insomnia in the general population. Due to the unique separation of D2 and 5HT2A ...
New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly
... and outdoor allergies. Twenty-nine percent of consumers said they view insomnia as more serious than indoor and outdoor allergies. In addition, while the ... do not overstate allergy symptoms. In addition, most physicians view insomnia (83 percent) and osteoarthritis (69 percent) as being less serious or ...... from 0.5 to 4.0 mg) will be compared to placebo. About Insomnia insomnia is a prevalent disorder that drives almost $5 billion in worldwide sales ... showed that 54% of the respondents experienced a minimum of one symptom of insomnia at least a few nights a week. Of those, respondents complained primarily ...
... reported central nervous system symptoms (including dizziness [28.1%], insomnia [16.3%], impaired concentration [8.3%], somnolence [7.0%], abnormal dreams ... fatigue (7%), headache (5%), rash (5%), sinusitis (4%), depression (4%), insomnia (4%), and abnormal dreams (4%). The dose of ATRIPLA is one tablet ...
... reported central nervous system symptoms (including dizziness [28.1%], insomnia [16.3%], impaired concentration [8.3%], somnolence [7.0%], abnormal dreams ... fatigue (7%), headache (5%), rash (5%), sinusitis (4%), depression (4%), insomnia (4%), and abnormal dreams (4%). The dose of ATRIPLA is one tablet ...
... in severity. The most frequently reported adverse events for VYVANSE were insomnia (8 percent), decreased appetite (6 percent), anorexia (4 percent) and ... were decreased appetite (4 percent), upper abdominal pain (4 percent), insomnia (2 percent), upper respiratory tract infection (2 percent) and vomiting (2 ...
... reported central nervous system symptoms (including dizziness [28.1%], insomnia [16.3%], impaired concentration [8.3%], somnolence [7.0%], abnormal dreams ... fatigue (7%), headache (5%), rash (5%), sinusitis (4%), depression (4%), insomnia (4%), and abnormal dreams (4%). The dose of ATRIPLA is one tablet ...
... reported central nervous system symptoms (including dizziness [28.1%], insomnia [16.3%], impaired concentration [8.3%], somnolence [7.0%], abnormal dreams ... fatigue (7%), headache (5%), rash (5%), sinusitis (4%), depression (4%), insomnia (4%), and abnormal dreams (4%). The dose of ATRIPLA is one tablet ...
... vs. 3%), headache (11.1% vs. 10%), constipation (11.1% vs. 5.6%), vomiting (11.1% vs. 5.6%), dyspepsia (11.1% vs. 3.3%), somnolence (11.1% vs. 3.3%), insomnia (10.0% vs. 3.3%) and sedation (10.0% vs. 4.4%). Lurasidone had a lower overall discontinuation rate (42.2%) compared to placebo (48.8%) with few ...
Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
... (ADHD) and Sympres(R) for the treatment of hypertension. The company also plans to develop drugs to treat menopausal flushing and potentially pain, insomnia and migraines, all of which are impacted by the adrenergic system. "ADX-N05 represents a significant advance toward expanding our product ...... were fatigue/asthenia (65 percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection ...
... were fatigue/asthenia (65 percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection ...
... cough (22%), arthralgia (21%), lower-limb edema (21%), malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased weight (16%), back pain (15%) and paresthesia (15%). Caution is advised when bisphosphonates are administered with ...
... injection site pain, peripheral oedema, dizziness, muscle spasms, nausea, contusion, diarrhoea, bone marrow disorder, influenza like illness, insomnia and pruritus. Reoccurrence of thrombocytopenia and bleeding after cessation of treatment and increased bone marrow reticulin have been ...
... of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections. See "Warnings ...
... (33% vs 16%), pyrexia (29% vs 19%), fatigue (29% vs 26%), lymphopenia (24% vs 17%), anorexia (23% vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% ...
... or equal to 5 percent higher patient incidence in Nplate versus placebo) were Arthralgia (26 percent, 20 percent), Dizziness (17 percent, 0 percent), insomnia (16 percent, 7 percent), Myalgia (14 percent, 2 percent), Pain in Extremity (13 percent, 5 percent) , Abdominal Pain (11 percent, 0 percent), ...
... (33% vs 16%), pyrexia (29% vs 19%), fatigue (29% vs 26%), lymphopenia (24% vs 17%), anorexia (23% vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% ...
... of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections. See "Warnings ...
... cough (22%), arthralgia (21%), lower-limb edema (21%), malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased weight (16%), back pain (15%) and paresthesia (15%). Caution is advised when bisphosphonates are administered with ...
... of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for ...
Other ContentsbifidabifidaspinaspinainjuriesinjuriesinjuriesinjuriesinjuriesmuscularmuscularmuscularmuscularmuscularmuscularmuscularspondylolisthesissplenomegalyspittingspirocheteOther TagsPhilippinesPersonsMadhyaTamifluReportsReportsReports
(Date:11/25/2009)...ach, may be used to boost resistance to, or slow, ...l of Medicine researchers report in a study publis...nce . , Parkinson,s disease is caused by a degen...rain known as the substantia nigra, which is respo...n of dopamine in late-stage Parkinson,s causes sym...
(Date:11/25/2009)...t pumps some 250 million liters of blood through t...s of the heart have to be extremely durable. The r...ce chair of the Department of Medicine III at Heid... A. Katus), has discovered a protein that is respo...unit, the sarcomere. In cooperation with other res...
(Date:11/24/2009)...understanding how sounds associated with Navy sona...if they hear it at all. , The same type of large... detect flaws in the space shuttle,s behemoth soli...inside the giant head of a whale. The scans are pr...hale,s hearing anatomy using a breakthrough method...
Breaking Biology News(10 mins):Hormone ghrelin can boost resistance to Parkinson's disease 2New genetic cause of cardiac failure discovered 2Rocket science leads to new whale discovery 2Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 1Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 2Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 3Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 4Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 5Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 6Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 7Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 8Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 9Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 10Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 11Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 12Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 13Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 14Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 15Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 16Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 17Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 18Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 19Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 20Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 21Reportlinker Adds Infections Ear Infections 6121 1Reportlinker Adds Infections Ear Infections 6121 2Reportlinker Adds Infections Ear Infections 6121 3Reportlinker Adds Infections Ear Infections 6121 4Reportlinker Adds Infections Ear Infections 6121 5Reportlinker Adds Infections Ear Infections 6121 6Anisakiasis hazard varies depending on the origin of the fish according to a study 61063 1Anisakiasis hazard varies depending on the origin of the fish according to a study 61063 2(Date:11/27/2009)..., , KELOWNA, BC, Nov. 27 /PRNewswire/ - Upl...eady seeing prime time in wellness. A combination ...ted data upload are solving a long term concern ov...ssible to accurately gauge and reward improved par...Technologies is one of the first wellness supplier...
(Date:11/27/2009)..., , NEUILLY-SUR-SEINE, France, Nov. 27 /...merican professional cycling team dedicated to eth...f cycling champions, announced today that it will ...f Transitions Optical as a new sponsor of the team...acturer of adaptive eyewear, offering the most adv...
(Date:11/27/2009)..., , SEATTLE, Nov. 27 /PRNe... site, received record-high Thanksgiving traffic n...y before Thanksgiving, providing a clear picture o...he year. The average Thanksgiving meal in 2009 wei... increase from last year,s feast. According to the...
(Date:11/26/2009)..., , NEW YORK, Nov. 27 With...than ever to employ good practices to control the ...need to be proactive not only to keep ourselves he...sick," said Eileen Finerty, RN, MS, CIC (certified...tion control and occupational health at Hospital f...
(Date:11/26/2009)...Fans get a bigger thrill when on an emotional roll.... 26 (HealthDay News) -- Call it the fear factor m...gests that spectators -- especially those who root...action if it,s a closely contested match and victo...ven despair. , Chew on that this Thanksgiving w...
Breaking Medicine News(10 mins):Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3[0] New USB technology adds accountability and convenience to wellness programs[0] Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor[0] It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories[1] Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use[0] Watching the Nail-Biting Big Game Hurts So Good
JudgmentKasturbaTiagabineTaurineAnonymousPhilippinesGemcitabinePrimrosePersonsShortnessMadhyaTamifluReportsSafest
Other Tagsperformed 2performed 3performed 4performed 5performed 6performed 7performed 8performed 9performed 10surgery 2surgery 3surgery 4surgery 5surgery 6surgery 7surgery 8surgery 9surgery 10bypass 2bypass 3bypass 4bypass 5bypass 6bypass 7bypass 8bypass 9bypass 10people 2people 3people 4people 5people 6people 7people 8people 9people 10short 2short 3short 4short 5short 6short 7short 8short 9short 10news 2news 3news 4news 5news 6news 7news 8news 9news 10calculate 2controversy 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |